Ocular Therapeutix announced the treatment of the first patient in a phase 1, open-label, proof-of-concept clinical trial being conducted in the United States for OTX-TIC, a bioresorbable travoprost implant delivered via an intracameral injection for the reduction of IOP in patients with glaucoma and ocular hypertension.
“One of the biggest unmet needs in ophthalmology, and in glaucoma in particular, is solving the problem of non-compliance,” Michael Goldstein, MD, Chief Medical Officer of Ocular Therapeutix, said in a company news release. “OTX-TIC is designed to directly address compliance issues by delivering travoprost over the course of several months with a single implant. We are excited to initiate this U.S. clinical trial in patients with glaucoma and ocular hypertension as we continue to advance our pipeline.”
In preclinical studies, OTX-TIC has demonstrated an acceptable safety profile and a marked reduction in IOP. OTX-TIC features a sustained release profile and is designed to support dosing with a duration of four to six months in a single administration.
This U.S.-based, phase 1, multicenter, open-label, prospective, proof-of-concept clinical trial will evaluate the safety, efficacy, durability, and tolerability of OTX-TIC in patients with primary open-angle glaucoma or ocular hypertension.
About OTX-TIC (travoprost implant) for Intracameral Use
OTX-TIC is a bioresorbable intracameral implant containing micronized travoprost that is injected into the anterior chamber of the eye and is intended for patients with glaucoma with a target duration of drug delivery of four to six months. Preclinical studies in beagles have demonstrated maintenance of drug levels in the aqueous humor and a sustained lowering of intraocular pressure.